abstract
- Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888-99. 35617986.
In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- October 2022
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Adenosine Monophosphate (MeSH)
- Adult (MeSH)
- Alanine (MeSH)
- Azetidines (MeSH)
- COVID-19 Drug Treatment (MeSH)
- Dexamethasone (MeSH)
- Double-Blind Method (MeSH)
- Humans (MeSH)
- Purines (MeSH)
- Pyrazoles (MeSH)
- Randomized Controlled Trials as Topic (MeSH)
- Sulfonamides (MeSH)
published in
- ACP journal club Journal